DUBLIN, July 11, 2017 /PRNewswire/ -- Allergan plc
(NYSE: AGN), a global leader in eye care for nearly 70 years, today
unveiled #EyePic, an exciting new online awareness campaign as part
of the See America initiative to fight preventable blindness and
visual impairment in the United
States. #EyePic will use the power of social media to
broaden awareness of preventable blindness, promote discussion
around eye health and ultimately encourage all Americans to visit
their eye doctors for comprehensive eye exams.
Experience the interactive Multichannel News Release here:
https://www.multivu.com/players/English/8134051-allergan-see-america-eyepic-campaign/
Allergan has partnered with television star Milo Ventimiglia, professional football player
Victor Cruz, and actress
Alexandra Daddario to engage with
their friends and followers through entertaining video content and
launch #EyePic by posting a photo of their eyes and tagging two
friends to do the same. For every #EyePic posted, See America will
donate $10 to the American Foundation
for the Blind*, a national non-profit founded in 1921 to
better the quality of life for Americans already suffering with
vision loss.
"Sight is one of life's most amazing and delicate gifts," said
Jag Dosanjh, SVP of US Eye Care at Allergan. "We're launching
#EyePic on social media to spread the word about preventable
blindness, in a forum where people can easily join the fight. With
the help of Milo, Victor, Alexandra and the many Americans who will
be posting their own #EyePic, we will encourage proactive eye care
and communicate important facts about preventable blindness in
America."
Not all blindness is preventable; today in the United States, there are more than 20
million Americans living with vision loss1. By
supporting the American Foundation for the Blind's vital programs
and services, Allergan is helping to create a more inclusive
society for Americans with visual impairments.
"We are grateful for Allergan's support," said Kirk Adams, President and CEO of the American
Foundation for the Blind. "The American Foundation for the Blind is
committed to creating a world with no limits for millions of
Americans who are blind or visually impaired, like myself; and we
are heartened that Allergan is supporting our mission."
To get involved with #EyePic, follow three easy steps:
1. Post a picture of your eyes
2. Add #EyePic
3. Tag two friends to do the same
To watch the videos and learn more about #EyePic, visit
www.SeeAmerica.vision.
*up to $50,000
About See America
Allergan, a global leader in eye care for nearly 70 years,
recently launched See America to fight against preventable
blindness and vision impairment in America. See America has set out
to make vision health a priority across the U.S., increase
awareness of diseases that cause preventable blindness, and bring
critical access to vision care to those who need it most. To find
out more about See America, visit www.SeeAmerica.vision
About The American Foundation For The Blind
The American Foundation for the Blind (AFB) is a
national nonprofit that expands possibilities for people with
vision loss. AFB fulfills its mission by broadening access to
technology; elevating the quality of information and tools for the
professionals who serve people with vision loss; and promoting
independent and healthy living for people with vision loss by
providing them and their families with relevant and timely
resources. Headquartered in New
York, AFB is proud to house the Helen Keller Archives &
Gallery and honor the more than 40 years that Helen Keller worked tirelessly for AFB.
About Allergan Plc.
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceutical, device,
biologic, surgical and regenerative medicine products for patients
around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of
research and development, which defines our approach to identifying
and developing game-changing ideas and innovation for better
patient care. With this approach, Allergan has built one of the
broadest development pipelines in the pharmaceutical industry with
70+ mid-to-late stage pipeline programs currently in
development.
Allergan's success is powered by our more than 18,000 global
colleagues' commitment to being Bold for Life. Together, we build
bridges, power ideas, act fast and drive results for our customers
and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Allergan Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective on existing trends and
information as of the date of this release. Actual results may
differ materially from Allergan's current expectations depending
upon a number of factors affecting Allergan's business. These
factors include, among others, the difficulty of predicting the
timing or outcome of FDA approvals or actions, if any; the impact
of competitive products and pricing; market acceptance of and
continued demand for Allergan's products; difficulties or delays in
manufacturing; and other risks and uncertainties detailed in
Allergan's periodic public filings with the Securities and Exchange
Commission, including but not limited to Allergan's Annual Report
on Form 10-K for the year ended December 31,
2016 and Allergan's Quarterly Report on Form 10-Q for the
period ended March 31, 2017. Except
as expressly required by law, Allergan disclaims any intent or
obligation to update these forward-looking statements.
References
1 National Center for Health
Statistics, National Health Interview Survey (NHIS),
2015, www.cdc.gov/nchs/nhis.htm.
View original
content:http://www.prnewswire.com/news-releases/see-america-furthers-the-fight-against-preventable-blindness-with-eyepic-campaign-300485757.html
SOURCE Allergan